AI assistant
REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2012
Dec 19, 2012
29977_dirs_2012-12-19_1d563487-417b-427f-9643-dd97aaa6d4e2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2012-12-18
Reporting Person: Aberman Michael S (VP Strategy and Investor Relat)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2012-12-18 | Common Stock | M | 1200.0 | $24.0 | Acquired | 11700.0 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2012-12-18 | Incentive Stock Option (right to buy) | $24.0 | M | 1200.0 | Disposed | 2020-03-22 | Common Stock (1200.0) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 287.0 | Indirect |
Footnotes
F1: The stock option award (combined incentive stock option and non-qualified stock option) vests over five years, commencing one year after the date of grant. 12,500 options vest on the first anniversary, 25,000 options vest on the second anniversary, 25,000 options vest on the third anniversary, 25,000 options vest on the fourth anniversary, and 12,500 options vest on the fifth anniversary of the date of grant.
F2: Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.